Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Aurigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurigene announces dose administration in first patient study for phase II study of psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Aurigene"},{"company":"SPARC","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"$20.0 million","newsHeadline":"SPARC, Sun Pharma Ink Pact to Develop & Commercialize SCD-044 to Treat Inflammatory Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"SPARC"},{"company":"Cadila Pharmaceuticals","sponsor":"Lipidor AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lipidor, Cadila to Conduct Ph III Study of Anti-Psoriasis Candidate","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Cadila Pharmaceuticals"}]

Cadila Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Lipidor, Cadila to Conduct Ph III Study of Anti-Psoriasis Candidate

Details:

Lipidor AB has penned an agreement with Cadila Pharmaceuticals to conduct a Phase III study for Lipidor’s drug candidate AKP-02. AKP-02 is an antipsoriasis medicine that combines the active substances calcipotriol and betamethasone with Lipidor’s spray-based AKVANO technology.

Lead Product(s): Calcipotriol,Betamethasone

Therapeutic Area: Dermatology Product Name: AKP-02

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Lipidor AB

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 07, 2020

ASK
US

Upload
your Pipeline Activity

SPARC

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SPARC, Sun Pharma Ink Pact to Develop & Commercialize SCD-044 to Treat Inflammatory Diseases

Details:

Sun Pharma has been granted a worldwide licence for the development and commercialization of SCD-044, which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders. SCD-044 is entering phase 2 clinical trials.

Lead Product(s): SCD-044

Therapeutic Area: Dermatology Product Name: SCD-044

Highest Development Status: Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited

Deal Size: $145.0 million Upfront Cash: $20.0 million

Deal Type: Licensing Agreement May 29, 2020

ASK
US

Upload
your Pipeline Activity

Aurigene

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Aurigene announces dose administration in first patient study for phase II study of psoriasis

Details:

The initiation of this phase II study represents a significant milestone for Aurigene, as it marks the first program which Aurigene has led from the bench side to the clinic all by itself.

Lead Product(s): AUR101

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 18, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY